Ropes & Gray Represents Baring Private Equity Asia in Sale of Lumenis to Boston Scientific
Ropes & Gray represented an affiliate of Baring Private Equity Asia in a definitive agreement to sell the surgical business of Lumenis Ltd. to Boston Scientific Corp. for $1.07 billion in cash, subject to closing adjustments. The transaction was announced on March 3. The press release is available here.
BPEA, one of the largest and most established private alternative investment firms in Asia with assets under management of approximately US$20 billion, will retain ownership of the Lumenis global aesthetics and ophthalmology businesses. Lumenis is a privately-held company that develops and commercializes energy-based medical solutions.
The Ropes & Gray team that represented Baring Private Equity Asia was led by private equity partners Neill Jakobe and Martin Ruhaak (both of Chicago), and included tax partner Andrew Howard (London), mergers & acquisitions counsel Thomas Burke (New York), data, privacy & cybersecurity partner Rohan Massey (London), life sciences, regulatory & compliance partners Gregory Levine (Washington D.C.) and Katherine Kai Ling Wang (Shanghai), employment, executive compensation & benefits partners Jennifer Cormier and Loretta Richard (both of Boston), private equity partners Elizabeth Todd, Will Rosen and Alexander Robb (all of London) and Eric Issadore (San Francisco), litigation & enforcement partners Jonathan Klarfeld (Washington D.C.), Ruchit Patel (London), Andrew Dale (Hong Kong) and Timothy Farrell (Chicago), mergers & acquisitions partner Matthew Jacobson (San Francisco), tax partner Elaine Murphy (Boston), health care partner Jennifer Romig (Chicago), and private equity associate David Dowling (London), William Zimmerman (Chicago), Walton Dumas (San Francisco) and Katherine McGuigan (New York), tax counsel Christopher Agnoli (London), and life sciences, regulatory & compliance associate Sarah Blankstein (Boston).